Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors
Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
In this phase I study, the investigators will determine the maximum tolerated doses of
imatinib and PTK/ZK administered in two different dose schedules. Due to the different
mechanisms of action and the minimally-overlapping toxicity profiles of these two novel oral
agents, it is hoped that a combination regimen incorporating both compounds will produce
increased activity without enhanced toxicity. After completion of this phase I study, the
investigators propose a follow-up phase II study in patients with previously treated
metastatic renal cell cancer - where VEGF and PDGF appear to play important roles in the
malignant phenotype - to determine the antitumor efficacy of the recommended dose of this
combination regimen.